Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

While there was no mention of coffee cost, this element is not particulary germane to this story. The article reported that drinking four eight-ounce cups of coffee was linked to a 30% reduction in the risk of developing diabetes. Rather than relative reduction, the article should have included the absolute reduction. The rate at which women who drank coffee developed type II diabetes was 6.05% while the rate in women who drank 4-5 cups of coffee per day was 4.30%. The relative difference always sounds more convincing; the absolute difference is what is probably most meaningful to viewers. So, in this case, a 30% relative difference equated to an absolute difference of less than 2%. There was no mention of potential harms that might be derived from increased coffee consumption. The article could have included concern about disrupted sleep, heart palpitations, increased urinary frequency, and jitteriness. Because of the design of the study covered in this story (a prospective epidemiologic study), it is not possible to conclude that increasing decaffeinated coffee consumption will decrease the risk of type II diabetes. This important point was covered by one of the physician quotes in the story. The speculation about what was in decaf coffee that resulted in the decreased risk of type II diabetes was not well grounded. Other than painting perhaps a little too rosy picture of all the potential benefits that might be gained from coffee consumption, this article did not practice disease mongering. It did not present any data on the prevalence of type II diabetes. The story could have mentioned that the Type II diabetes has become rather common place and is a public health issue. It appears that this story is based on a research study in the Archives of Internal Medicine and from comments by one physician and one researcher. It certainly would have been better to actually mention where the study was published rather than referring to it as "the study out today". It would also have been better to give us some perspective about the value of the quotes provided by giving some background on the two people interviewed. Nonethless, we credit the story for having different perspectives. There was no mention of other lifestyle strategies that an individual might pursue in order to lower the risk of type II diabetes. This is a particularly important public health message. Moderate daily physical activity, such as walking, has also been shown to lower the risk of type II diabetes. The story isn't about a treatment per se, but about the effects of drinking coffee, which is readily available to all. The story is quite clear about the widespread availability and use of coffee. There is a growing body of literature suggesting that coffee drinking can lower one's risk of type II diabetes. This story covered the latest such evidence, and made it clear that this is part of a growing body of "more intriguing evidence." There is no evidence that this story relied solely or largely on a news release.
Coffee found to reduce risk of diabetes

Researchers studied the medical records of more than 1 million children and young adults aged 2 to 24 who were taking or had taken stimulants such as Ritalin or Adderall and found no sign of increased risk of heart problems. "We don't see any evidence of increased risk," said Dr. William Cooper of Vanderbilt University, whose study was published in the New England Journal of Medicine. The study in children is the first of three commissioned by the Food and Drug Administration to understand the potential heart risks of the drugs after U.S. and Canadian regulators received a number of reports in 2006 of heart attacks, strokes and sudden cardiac arrest in children taking the medications. The reports prompted several FDA advisory committee hearings on heart problems, and Health Canada temporarily suspended marketing of ADHD drugs. The concerns also prompted the American Heart Association to issue guidelines suggesting that children who were just starting to take the drugs should be tested for potential underlying heart problems. "There was a lot of concern and confusion among families and providers about what the best approach would be to treating kids who had ADHD and who might benefit from these medicines," Cooper said by phone. ADHD is one of the most common child mental disorders, affecting around 3 to 5 percent of children globally. Children with ADHD are excessively restless, impulsive and easily distracted, and often have trouble at home and in school. There is no cure, but the symptoms can be kept in check by a combination of behavioral therapy and medication. In the United States, some 2.7 million children have prescriptions for ADHD drugs including Novartis' Ritalin or methylphenidate and Focalin; Johnson & Johnson's Concerta, Shire's Adderall and Vyvanse and Eli Lilly's Strattera. For the study, Cooper's team used prescription data from four large, geographically and demographically diverse health plans on 1,200,438 children and youth, including both current and past users of the drugs. They checked health records for evidence of heart problems, including heart attacks, strokes and sudden cardiac deaths, in children who were currently taking the drugs or who had taken them. The team found no increased risk of heart problems for either current or past users of the drugs. Yet because there were so few cases of serious heart problems just 81 the study may not have been large enough to detect it. But even if there were a risk of heart problems, it is extremely slight, Cooper said. In a guidance document issued on Tuesday, the FDA said it continues to recommend that the drugs not be used in patients with serious heart problems. It added that patients should be monitored for changes in heart rate or blood pressure. Jefferies analyst Peter Welford said the findings will likely reassure investors in Shire, maker of Adderall and Vyvanse. But because there were so few heart problems, the study was underpowered and cannot conclusively dispel concerns about cardiovascular risks. Shire's shares were flat on Tuesday, outperforming a sharply lower market.
ADHD drugs do not increase heart problems in kids.

The oral drug delivery specialist said its insulin capsule had met all primary and secondary endpoints in a Phase IIa clinical trial and it now plans to launch a larger mid-stage study in the third quarter. Shares in the Nasdaq-listed company opened 10 percent higher at $28.50 on the news. The stock has surged from around $4 since the end of 2012 on rising hopes for its insulin pill. The concept of oral insulin as a way to relieve diabetics of several daily injections has been around since the 1930s, but making it a reality is extremely difficult because insulin is destroyed by enzymes in the digestive system. Oramed believes that it has now found a solution to allow enough insulin to survive the onslaught of digestive juices to still do some good. At least 90 percent of the more than 382 million diabetes sufferers worldwide are in the type 2 category, according to the International Diabetes Foundation, which expects the number of diabetes patients to near 600 million by 2035. Consensus analyst forecasts suggest that the overall diabetes drug market, worth $37 billion a year at present, will reach more than $57 billion by 2018, according to Thomson Reuters Pharma. Oral insulin could make it easier for sufferers to start early treatment, slow progression of the disease and delay the need for injections, Oramed said. Unlike injections, the ingested form passes first into the liver, which regulates the secretion of insulin into the bloodstream. The new year-long Phase IIb study in the United States will study 150 type 2 diabetes patients and mainly test for the drug's effectiveness, Chief Executive Nadav Kidron told Reuters after the company issued results of the Phase IIa trial. During the Phase IIa trial, conducted under a new U.S. Food and Drug Administration (FDA) drug protocol, 30 patients with type 2 diabetes entered an in-patient setting for one week. "The FDA wanted us to show one thing - that it was safe so they will let us do a IIb trial," Kidron said. While Oramed was not checking for efficacy, Kidron said the IIa trial revealed that it was effective, though the sample size was too small for FDA purposes. Oramed will also need to conduct a final large-scale Phase III trial before the drug is licensed for sale, so the capsule is still years away from hitting the market. The company is, however, ahead of Novo Nordisk, which has yet to start Phase II testing. Oramed is hoping to partner with large pharmaceutical firms for development and sales of the drug. But Kidron said that only preliminary discussions have taken place so far. The company also plans to initiate a Phase IIa FDA study for type 1 diabetes in the near term. The global expense for diabetes is about $500 billion and an oral version could bring a large drop in costs. Oramed noted that the pill would not eliminate the eventual need for injections but could delay the shift to needles by many years.
Israel's Oramed a step closer in race for first insulin pill.